192 related articles for article (PubMed ID: 31874799)
1. Apolipoprotein E-related glomerular disorders.
Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E
Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799
[TBL] [Abstract][Full Text] [Related]
2. A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes.
Kato T; Ushiogi Y; Yokoyama H; Hara S; Matsunaga A; Muso E; Saito T
CEN Case Rep; 2019 May; 8(2):106-111. PubMed ID: 30701487
[TBL] [Abstract][Full Text] [Related]
3. A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka.
Hirashima H; Komiya T; Toriu N; Hara S; Matsunaga A; Saito T; Muso E
Clin Nephrol Case Stud; 2018; 6():45-51. PubMed ID: 30542638
[TBL] [Abstract][Full Text] [Related]
4. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.
Sakatsume M; Kadomura M; Sakata I; Imai N; Kondo D; Osawa Y; Shimada H; Ueno M; Miida T; Nishi S; Arakawa M; Gejyo F
Kidney Int; 2001 May; 59(5):1911-8. PubMed ID: 11318963
[TBL] [Abstract][Full Text] [Related]
5. Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2.
Fukunaga M; Nagahama K; Aoki M; Shimizu A; Hara S; Matsunaga A; Muso E; Saito T
Case Rep Nephrol Dial; 2018; 8(1):45-55. PubMed ID: 29692990
[TBL] [Abstract][Full Text] [Related]
6. Macrophage Infiltration into the Glomeruli in Lipoprotein Glomerulopathy.
Takasaki S; Maeda K; Joh K; Yamakage S; Fukase S; Takahashi T; Suzuki M; Matsunaga A; Saito T
Case Rep Nephrol Dial; 2015; 5(3):204-12. PubMed ID: 26955632
[TBL] [Abstract][Full Text] [Related]
7. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy.
Tokura T; Itano S; Kobayashi S; Kuwabara A; Fujimoto S; Horike H; Satoh M; Komai N; Tomita N; Matsunaga A; Saito T; Sasaki T; Kashihara N
J Atheroscler Thromb; 2011; 18(6):536-41. PubMed ID: 21467726
[TBL] [Abstract][Full Text] [Related]
8. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy.
Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W
J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800
[TBL] [Abstract][Full Text] [Related]
9. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
Saito T; Matsunaga A; Oikawa S
Am J Kidney Dis; 2006 Feb; 47(2):199-211. PubMed ID: 16431249
[TBL] [Abstract][Full Text] [Related]
10. Topics in lipoprotein glomerulopathy: an overview.
Saito T; Matsunaga A; Ito K; Nakashima H
Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
[TBL] [Abstract][Full Text] [Related]
11. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
[TBL] [Abstract][Full Text] [Related]
12. Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy.
Saito T; Ishigaki Y; Oikawa S; Yamamoto TT
Trends Cardiovasc Med; 2002 Feb; 12(2):67-70. PubMed ID: 11852253
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.
da Silveira-Neto JN; de Oliveira Ahn GJ; de Menezes Neves PDM; Baptista VAF; de Almeida Araújo S; Wanderley DC; Watanabe A; Watanabe EH; Murai NM; Bertollo EMG; Vieira-Neto OM; Dantas M; de Antônio SR; Costa RS; Baptista MASF; Moysés-Neto M; Onuchic LF
Diagn Pathol; 2021 Jul; 16(1):65. PubMed ID: 34311745
[TBL] [Abstract][Full Text] [Related]
14. A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.
Stratikos E; Chroni A
Clin Exp Nephrol; 2014 Apr; 18(2):225-9. PubMed ID: 24149834
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics and gene mutations in 11 patients with lipoprotein glomerulopathy.
Qin Y; Sun XJ; Hu YF; Jing M; Yu XJ; Zhao MH; Tan Y
Ren Fail; 2024 Dec; 46(1):2332491. PubMed ID: 38584145
[TBL] [Abstract][Full Text] [Related]
16. An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.
Li MS; Li Y; Liu Y; Zhou XJ; Zhang H
Front Med (Lausanne); 2022; 9():905007. PubMed ID: 35602473
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
Marais AD
Pathology; 2019 Feb; 51(2):165-176. PubMed ID: 30598326
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein glomerulopathy in China.
Chen Y
Clin Exp Nephrol; 2014 Apr; 18(2):218-9. PubMed ID: 24165683
[TBL] [Abstract][Full Text] [Related]
19. Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka and Homozygous Apolipoprotein E2/2 without Dyslipidemia, with Characteristic Electron-Dense Deposits.
Koshino A; Takaeda C; Matsuno T; Kitajima S; Iwata Y; Sakai N; Nagahama K; Niida Y; Saito T; Yokoyama H; Wada T
Case Rep Nephrol Dial; 2022; 12(2):96-104. PubMed ID: 35950048
[TBL] [Abstract][Full Text] [Related]
20. A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I.
Takasaki S; Matsunaga A; Joh K; Saito T
CEN Case Rep; 2018 May; 7(1):127-131. PubMed ID: 29356944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
